DenovAI Biotech
Kashif Sadiq is the Founder and CEO of DenovAI Biotech, leading the company towards a protein design revolution to improve human health and the world. Prior to this, Kashif worked as a Biophysicist and Data Scientist at EMBL and as a Senior Research Fellow at the Heidelberg Institute for Theoretical Studies (HITS). Kashif also served as a Mathilde Krim Fellow at Universitat Pompeu Fabra and founded Science English Editors Ltd to assist scientists in publishing their research. Kashif's educational background includes a Ba MSci in Natural Sciences from the University of Cambridge and a PhD in Theoretical and Computational Molecular Biophysics from UCL.
This person is not in any teams
This person is not in any offices
DenovAI Biotech
DenovAI Biotech (https://denovai.com/) is an exciting new start-up based at the dynamic AION Labs Venture Hub (https://aionlabs.com) in Rehovot, Israel. AION Labs is a first-of-its-kind alliance of global pharma and technology leaders and investors - Astrazeneca, Merck, Pfizer, Teva, the Israel Biotech Fund and Amazon Web Services (AWS) – powered by BioMed X and with support from the Israel Innovation Authority - that have come together with one clear mission: to create and adopt gateway AI and computational technologies that will transform the process of drug discovery and development for the betterment of human health. At DenovAI, we believe that humanity is on the cusp of a protein design revolution that stands to transform the world around us. And we are passionate about building the platform and team that will lead us there. We are harnessing the power of artificial intelligence and computational molecular biophysics to develop foundational technology platforms that can design proteins de novo. We are at the start of a journey to design next generation therapeutics like high-affinity antibodies, small protein and peptide biologics, and diagnostic reporters - all tailored to bind to their specific targets. Antibody therapeutics: Our AI-based platform for rapid de novo antibody discovery will design high-affinity binders to epitopes of choice, reduce the discovery process from months to days and broaden the scope of therapy to many more diseases. Small protein binders: Building on recent innovations our platform for de novo protein design can design bespoke high-affinity binders for targets of choice – unlocking many applications in biologics and diagnostics